BIAF stock has given up its prior gain. bioAffinity Technologies shares were trading higher after the company announced that the Japan Patent Office issued a Notice of Allowance indicating its intention to grant a patent for the method of predicting the likelihood of lung cancer powered by the CyPath Lung test for early-stage lung cancer.